These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15018709)

  • 41. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression.
    Nabatov AA; van Montfort T; Geijtenbeek TB; Pollakis G; Paxton WA
    FEBS J; 2006 Nov; 273(21):4944-58. PubMed ID: 17010165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
    Cormier EG; Dragic T
    J Virol; 2002 Sep; 76(17):8953-7. PubMed ID: 12163614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays.
    Moore JP; Cao Y; Conley AJ; Wyatt R; Robinson J; Gorny MK; Zolla-Pazner S; Ho DD; Koup RA
    J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):332-9. PubMed ID: 7510807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
    Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
    J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV-1 gp120-CXCR4 recognition probed with synthetic nanomolar affinity D-peptides containing fragments of gp120 V3 loop.
    Zhu R; Meng Q; Zhang H; Zhang G; Huang LSM; Xu Y; Schooley RT; An J; Huang Z
    Eur J Med Chem; 2022 Dec; 244():114797. PubMed ID: 36270088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence.
    Kumar R; Raghava GP
    PLoS One; 2013; 8(4):e61437. PubMed ID: 23596523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.
    Nolan KM; Del Prete GQ; Jordan AP; Haggarty B; Romano J; Leslie GJ; Hoxie JA
    J Virol; 2009 Apr; 83(8):3798-809. PubMed ID: 19193800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies.
    Mor A; Segal E; Mester B; Arshava B; Rosen O; Ding FX; Russo J; Dafni A; Schvartzman F; Scherf T; Naider F; Anglister J
    Biochemistry; 2009 Apr; 48(15):3288-303. PubMed ID: 19281264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of a dual-tropic human immunodeficiency virus (HIV-1) strain derived from the prototypical X4 isolate HXBc2.
    Xiang SH; Pacheco B; Bowder D; Yuan W; Sodroski J
    Virology; 2013 Mar; 438(1):5-13. PubMed ID: 23369572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages.
    Rabehi L; Seddiki N; Benjouad A; Gluckman JC; Gattegno L
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1605-15. PubMed ID: 9870313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.
    Moulard M; Lortat-Jacob H; Mondor I; Roca G; Wyatt R; Sodroski J; Zhao L; Olson W; Kwong PD; Sattentau QJ
    J Virol; 2000 Feb; 74(4):1948-60. PubMed ID: 10644368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5.
    Isaka Y; Sato A; Miki S; Kawauchi S; Sakaida H; Hori T; Uchiyama T; Adachi A; Hayami M; Fujiwara T; Yoshie O
    Virology; 1999 Nov; 264(1):237-43. PubMed ID: 10544150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection.
    Li Y; Rey-Cuille MA; Hu SL
    AIDS Res Hum Retroviruses; 2001 Nov; 17(16):1473-9. PubMed ID: 11709091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
    Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
    Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. On the Physicochemical and Structural Modifications Associated with HIV-1 Subtype B Tropism Transition.
    Lamers SL; Fogel GB; Liu ES; Salemi M; McGrath MS
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):829-40. PubMed ID: 27071630
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alterations in HIV-1 gp120 V3 region are necessary but not sufficient for coreceptor switching in CRF07_BC in China.
    Zhang L; Ma L; Wang Z; Wang Y; Zhang J; Wang H; Shao Y
    PLoS One; 2014; 9(3):e93426. PubMed ID: 24676404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.
    Nabatov AA; Pollakis G; Linnemann T; Kliphius A; Chalaby MI; Paxton WA
    J Virol; 2004 Jan; 78(1):524-30. PubMed ID: 14671134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.